Cryptogenic fibrosing alveolitis: Diagnosis and treatment

Hospital Medicine

Volumn 59, Issue 5, 1998, Pages 364-368

  Egan, J J ^a   Hasleton, P S ^a  

^a Department of Pathology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

HUMAN; LUNG; LUNG FIBROSIS; RADIOGRAPHY; REVIEW;

CYCLOSPORINE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; PREDNISOLONE; PULMONARY FIBROSIS;

EID: 0032065402     PISSN: 14623935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Agusti C, Xaubet A, Agusti AGN, Roca J, Ramirez J, Rodriguez-Rosin R (1994) Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow up. Eur Respir J 7: 643-50
2. Alton EWF, Johnson M, Turner-Warwick M (1989) Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med 83: 277-9
3. Dayton CS, Schwartz DA, Helmers RA et al (1993) Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy. Implications for future studies. Chest 103: 69-73
4. Egan JJ, Stewart JP, Hasleton PS, Arrand JR, Carroll KB, Woodcock AA (1995) Epstein-Barr virus replication within pulmonary epithelial cells, in cryptogenic fibrosing alveolitis. Thorax 50: 1234-9
5. Hasleton PS (1996) Fibrosing alveolitis. In: Hasleton PS, ed. Spencer's Pathology of the Lung. 5th edn. McGraw Hill, New York: 401-32
6. Hosenpud JD, Novick RJ, Bennett LE, Keck BM, Fiol B, Daily P (1996) The registry of the international society for heart and lung transplantation: thirteenth official report1996. J Heart Lung Transplant 15: 655-74
7. Hubbard R, Lewis S. Richards K, Johnston I, Britton J (1996) Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 347: 284-9
8. Johnson MA, Kwan S, Snell NJC, Nunn AJ, Darbyshire JH, Turner Warwick M (1989) Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44: 280-8
9. Johnston I, Britton J, Kinnear W, Logan R (1990) Rising mortality from cryptogenic fibrosing alveolitis. Br Med J 301: 1017-21
10. Keogh BA, Crystal RG (1982) The key to the interstitial disorders. Thorax 37: 1-10
11. Lynch DA (1996) Ground glass attenuation on CT in patients with idiopathic pulmonary fibrosis. Chest 110: 312-13
12. Moolman JA, Bardin PC, Rossouw DJ, Joubert JR (1991) Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 46: 592-5
13. Peters SG, McDougall JC, Douglas WW, Coles DT, DeRemee RA (1993) Colchicine in the treatment of pulmonary fibrosis. Chest 103: 101-4
14. Raghu G, Depaso WJ, Cain K et al (1991) Azathioprine combined with prednisolone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomised, placebo controlled clinical trial. Am Re\' Respir Dis 144: 291-6
15. Scott J, Johnston I, Britton J (1990) What causes cryptogenic fibrosing alveolitis? A case control study of environmental exposure to dust. Br Med J 301: 1015-17
16. Stack BHR, Choo-Kang YFJ, Heard BE (1972) The prognosis of cryptogenic fibrosing alveolitis. Thorax 27: 535
17. Turner-Warwick M, Burrows B. Johnson A (1980) Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 35: 593-9
18. Vergnon JM, Vincent M, De The G, Mornex JF, Weynets P, Brune J (1984) Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association. Lancet ii: 768-70
19. Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, DuBois RM (1993) The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 148: 1076-82
20. Wells AU, Hansell DM, Harrison NK, Lawrence R, Black SM, Du Bois RM (1993) Clearance of inhaled Tc-DTPA predicts the clinical course of fibrosing alveolitis. Eur Resp J 6: 797-802